Intensive immunosuppression therapy for aplastic anemia associated with dyskeratosis congenita.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed, 31 citations in OpenAlex.

1. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita.Blood · 2007
   Trial
2. Genetic Counseling and Family Screening Recommendations in Patients with Telomere Biology Disorders.Current hematologic malignancy reports · 2023
   Review
3. Telomere biology: from disorders to hematological diseases.Frontiers in oncology · 2023
   Review
4. Telomere biology disorders: time for moving towards the clinic?Trends in molecular medicine · 2022
   Review
5. Molecular insight of dyskeratosis congenita: Defects in telomere length homeostasis.Journal of clinical and translational research · 2022
   Review
6. An update on the biology and management of dyskeratosis congenita and related telomere biology disorders.Expert review of hematology · 2019
   Review
7. Evaluation and Management of Hematopoietic Failure in Dyskeratosis Congenita.Hematology/oncology clinics of North America · 2018
   Review
8. How I diagnose and manage individuals at risk for inherited myeloid malignancies.Blood · 2016
   Article
9. Response to androgen therapy in patients with dyskeratosis congenita.British journal of haematology · 2014
   Article
10. Cytokine production by bone marrow mononuclear cells in inherited bone marrow failure syndromes.British journal of haematology · 2013
    Article
11. Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2013
    Article
12. Telomere biology in hematopoiesis and stem cell transplantation.Blood reviews · 2011
    Review
13. The genetics and clinical manifestations of telomere biology disorders.Genetics in medicine : official journal of the American College of Medical Genetics · 2010
    Review
14. Pathophysiology and management of inherited bone marrow failure syndromes.Blood reviews · 2010
    Review
15. Dyskeratosis congenita: the first NIH clinical research workshop.Pediatric blood & cancer · 2009
    Article
16. Dyskeratosis congenita.Hematology/oncology clinics of North America · 2009
    Article
17. Telomere maintenance and human bone marrow failure.Blood · 2008
    Review
18. TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita.American journal of human genetics · 2008
    Article
19. The role of telomere biology in bone marrow failure and other disorders.Mechanisms of ageing and development
    Review

Corrections and comments

• Comment on
  Intensive immunosuppression therapy for aplastic anemia associated with dyskeratosis congenita: report of a case.2005

Authors and funding

3 authors at 2 institutions in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as